Top 20 Global Respiratory Inhalers Manufacturers 2019

呼吸器吸入器製造の世界トップ20社2019

◆タイトル:Top 20 Global Respiratory Inhalers Manufacturers 2019
◆商品コード:VGN906170
◆調査・発行会社:visiongain
◆発行日:2019年4月
◆ページ数:144
◆レポート形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:産業未分類
◆販売価格オプション(消費税別)
Sigle UserGBP3,499 ⇒換算¥500,357見積依頼/購入/質問フォーム
Departmental/Five UserGBP3,899 ⇒換算¥557,557見積依頼/購入/質問フォーム
Site LicenseGBP4,999 ⇒換算¥714,857見積依頼/購入/質問フォーム
※Single UserとDept Licence(Five User)の場合、DRM(デジタル著作権管理)付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongainの日本における正規販売代理店です。

【レポートの概要】

本調査レポートでは、"呼吸器吸入器製造の世界トップ20社2019"について調査・分析し、レポートサマリー、市場の促進要因、抑制要因、市場動向、世界市場規模・市場予測、研究開発パイプライン分析、主要企業分析、結論などの情報をお届けいたします。

The global respiratory inhalers market is estimated to reach $38bn in 2023. In the respiratory Inhalers market the top three companies by revenue are GlaxoSmithKline, Boehringer Ingelheim and AstraZeneca, with 57.1% of the world market in 2018.How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 144-page report you will receive 77 charts– all unavailable elsewhere.
The 144-page report provides clear detailed insight into the top 20 global respiratory inhalers manufacturers. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand-new report today you stay better informed and ready to act.
Report Scope
• Global Top 20 Respiratory Inhalers Market forecasts to 2028
• Profiles of the 20 leading respiratory inhalers manufacturers:
• Aerocrine
• AMIKO Digital Health
• AstraZeneca
• BEXIMCO Pharmaceuticals
• Boehringer Ingelheim
• Chiesi Farmaceutici S.p.A.
• CIPLA
• FLUIDDA
• GlaxoSmithKline
• H&T Presspart
• Merck
• Mundipharma
• Novartis
• Omron Healthcare
• PARI Medical Holding
• PNEUMA Respiratory
• PULMATRIX
• Roche
• Sunovion Pharmaceuticals
• Teva

• The content of each profile differs, depending on the organization. In general, a profile gives the following information:
• An overview and analysis of the company
• A portfolio of the company’s marketed product and product pipeline
• Financial Information
• Revenue forecast to 2028
• Recent developments
• Future Outlook
• Analysis of the drivers and restraints of the global respiratory inhalers market
• Coverage of respiratory inhalers in the R&D pipeline. Discussions of research and development – see progress in this industry, finding technological, clinical and commercial outlooks and opportunities
• Key questions Answered by This Report:
• How is the Respiratory Inhalers Manufacturers market evolving?
• What is driving and restraining the Respiratory Inhalers Manufacturers market?
• What will be the main driver for the overall market to 2028?
• Will leading Respiratory Inhalers Manufacturers broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• Who are the leading players and what are their prospects over the forecast period?
Visiongain’s study is intended for anyone requiring commercial analyses for the top 20 global respiratory inhalers manufacturers. You find data, trends and predictions.
Buy our report today Top 20 Global Respiratory Inhalers Manufacturers 2019: GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Roche, Novartis, Merck, Teva, Other Companies.

【レポートの目次】

1 Report Overview
1.1 Global Respiratory Inhalers Manufacturers Market Overview
1.2 Global Respiratory Inhalers Manufacturers Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered by This Analytical Report
1.6 Who Is This Report for?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Visiongain Reports
1.10 About Visiongain

2 Introduction to Respiratory Inhalers
2.1 Respiratory Inhalers Overview
2.1.1 Nebulizers
2.1.2 Metered Dose Inhaler
2.1.3 Breath-Actuated Pressurised Metered-Dose Inhalers
2.1.4 Pressurised Metered-Dose Inhalers Plus Spacer Devices
2.1.5 Dry powder inhalers (DPIs)
2.1.6 Soft Mist Inhalers
2.2 COPD Respiratory Inhalers Overview
2.2.1 Chronic Obstructive Pulmonary Disease Medications
2.2.1.1 Bronchodilators
2.2.1.2 Glucocorticoids
2.3 Asthma Respiratory Inhalers Overview
2.3.1 Desirable inhaler characteristics for treating asthma
2.4 Respiratory Inhalers – Realising Their Potential, Market Drivers
2.4.1 Combination Therapies – Respiratory Inhalers
2.4.1.1 LAMA/LABA combinations
2.4.1.2 LABA/ICS combination
2.4.1.3 LABA+LAMA vs. LABA+ICS combinations
2.4.2 Triple Combination – Respiratory Inhalers
2.4.2.1 LAMA/LABA/ICS “triple combination inhalers”
2.5 Market Restraints
2.6 Respiratory Inhalers: Trends and Developments
2.6.1 E-Technology in Asthma and COPD

3 Leading Respiratory Inhalers Products: Overview, 2018
3.1 The Global Respiratory Inhalers Market In 2018
3.2 Leading Companies in the Respiratory Inhalers Market, 2018
3.3 How Will Leading Companies’ Market Shares Change to 2028?

4 Leading Respiratory Inhalers Manufacturers Worldwide, 2018
4.1 Astrazeneca – Company Overview & Analysis
4.1.1 AstraZeneca Marketed Respiratory Inhalers
4.1.1.1 Latest developments related to Key Marketed Products
4.1.1.1.1 Symbicort: Recent Developments
4.1.1.1.2 Bevespi Aerosphere: Recent Developments
4.1.1.1.3 Tudorza/ Eklira Genuair: Recent Developments
4.1.1.1.4 Duaklir: Recent Developments
4.1.1.1.5 Fasenra: Recent Developments
4.1.1.1.6 Other Recent Developments
4.1.2 AstraZeneca Respiratory Inhalers R&D Pipeline & Future Outlook
4.1.2.1 Latest developments related to Key Pipeline Products
4.1.2.1.1 PT010/ PT009/ PT008/ PT005: Pipeline Developments
4.1.2.1.2 Fasenra: Pipeline Developments
4.1.2.1.3 Tezepelumab: Pipeline Developments
4.1.2.1.4 Tralokinumab: Pipeline Developments
4.1.3 AstraZeneca Respiratory Market Forecast, 2017-2028
4.2 Glaxosmithkline – Company Overview & Analysis
4.2.1 GlaxoSmithKline Marketed Respiratory Inhalers
4.2.1.1 Latest Developments related to Key Marketed Products
4.2.1.1.1 Relvar/Breo Ellipta: Recent Developments
4.2.1.1.2 Anoro Ellipta: Recent Developments
4.2.1.1.3 Nucala: Recent Developments
4.2.1.1.4 Seretide/Advair: Recent Developments
4.2.1.1.5 Trelegy Ellipta: Recent Developments
4.2.1.1.6 Breo Ellipta, Advair Diskus and Advair HFA: Recent Developments
4.2.2 GlaxoSmithKline Respiratory Inhalers R&D Pipeline & Future Outlook
4.2.2.1 Latest developments related to Key Pipeline Products
4.2.2.1.1 Nucala: Recent Developments
4.2.3 GlaxoSmithKline Respiratory Market Forecast, 2017-2028
4.3 Boehringer Ingelheim – Company Overview & Analysis
4.3.1 Boehringer Ingelheim Marketed Respiratory Inhalers
4.3.1.1 Latest Developments related to Key Marketed Products
4.3.1.1.1 Spiriva Respimat: Recent Developments
4.3.1.1.1 Spiolto Respimat: Recent Developments
4.3.1.1.2 Ofev: Recent Developments
4.3.2 Boehringer Ingelheim Respiratory Inhalers R&D Pipeline & Future Outlook
4.3.3 Boehringer Ingelheim Respiratory Market Forecast, 2017-2028
4.4 Teva – Company Overview & Analysis
4.4.1 Teva Marketed Respiratory Inhalers
4.4.1.1 Latest developments related to Key Marketed Products
4.4.1.1.1 QVAR: Recent Developments
4.4.1.1.2 ProAir HFA: Recent Development
4.4.1.1.3 DuoResp Spiromax: Recent Developments
4.4.1.1.4 Aerivio Spiromax: Recent Developments
4.4.1.1.5 CINQAIR/CINQAERO: Recent Developments
4.4.1.1.6 AirDuo RespiClick / ArmonAir RespiClick: Recent Development
4.4.2 Teva Respiratory Inhalers R&D Pipeline & Future Outlook
4.4.2.1 Latest developments related to Key Pipeline Products
4.4.2.1.1 ProAir e-RespiClick: Recent Developments
4.4.3 Teva Respiratory Market Forecast, 2017-2028
4.5 Merck – Company Overview & Analysis
4.5.1 Merck Marketed Respiratory Inhalers
4.5.1.1 Latest Developments related to Key Marketed Products
4.5.1.1.1 Dulera: Recent Development
4.5.2 Merck Respiratory Inhalers R&D Pipeline & Future Outlook
4.5.3 Merck Respiratory Market Forecast, 2017-2028
4.6 Roche – Company Overview & Analysis
4.6.1 Roche Marketed Respiratory Inhalers
4.6.1.1 Latest Developments related to Key Marketed Products
4.6.1.1.1 Xolair: Recent Developments
4.6.2 Roche Respiratory Inhalers R&D Pipeline & Future Outlook
4.6.2.1 Latest Developments related to Key Pipeline Products
4.6.2.1.1 RG3637: Pipeline Developments
4.6.3 Roche Respiratory Market Forecast, 2017-2028
4.7 Novartis – Company Overview & Analysis
4.7.1 Novartis Marketed Respiratory Inhalers
4.7.1.1 Latest developments related to Key Marketed Products
4.7.1.1.1 Ultibro Breezhaler: Recent Developments
4.7.1.1.2 Xolair: Recent Developments
4.7.2 Novartis Respiratory Inhalers R&D Pipeline & Future Outlook
4.7.2.1 Latest developments related to Key Pipeline Products
4.7.2.1.1 QAW039: Pipeline Developments
4.7.2.1.2 QBW251: Pipeline Developments
4.7.2.1.3 QVM149: Pipeline Developments
4.7.2.1.4 CSJ117: Pipeline Developments
4.7.2.1.5 CJM112: Pipeline Developments
4.7.3 Novartis Respiratory Market Forecast, 2017-2028
4.8 Mundipharma – Company Overview & Analysis
4.8.1 Mundipharma Marketed Respiratory Inhalers
4.8.1.1 Latest Developments related to Key Marketed Products
4.8.1.1.1 Flutiform (fluticasone propionate and formoterol): Recent Developments
4.8.1.1.2 Company Related Developments
4.8.2 Mundipharma Respiratory Inhalers R&D Pipeline & Future Outlook
4.8.2.1 Latest Developments related to Key Pipeline Products
4.8.2.1.1 Flutiform k-haler (fluticasone propionate and formoterol): Recent Developments
4.9 Pari Medical Holding – Company Overview & Analysis
4.9.1 PARI Medical Holding Marketed Respiratory Inhalers
4.9.1.1 Latest Developments related to Key Marketed Products
4.9.1.1.1 SUN-101: Recent Developments
4.9.2 PARI Pharma Respiratory Inhalers R&D Pipeline & Future Outlook
4.9.2.1 Latest Developments related to Key Pipeline Products
4.9.2.1.1 Cyclosporin A: Recent Developments
4.10 Omron Healthcare Europe B.V– Company Overview & Analysis
4.10.1 Omron Healthcare Europe B.V: Marketed Respiratory Products
4.10.1.1 Latest Developments related to Company
4.10.1.1.1 Company Recent Developments
4.11 Cipla– Company Overview & Analysis
4.11.1 Cipla Marketed Respiratory Inhalers
4.11.1.1 Latest Developments related to Key Marketed Products
4.11.1.1.1 Budesonide Inhalation Suspension: Pipeline Developments
4.11.1.1.2 SynchroBreathe: Pipeline Developments
4.11.1.2 Cipla Launch Plans for Respiratory Products
4.12 Sunovion Pharmaceuticals– Company Overview & Analysis
4.12.1 Sunovion Pharmaceuticals: Marketed Respiratory Inhalers
4.12.1.1 Latest Developments related to Key Marketed Products
4.12.1.1.1 SUN-101: Recent Developments
4.12.2 Sunovion Pharmaceuticals Respiratory Inhalers R&D Pipeline & Future Outlook
4.12.3 Sunovion Respiratory Market Forecast, 2017-2028
4.13 Aerocrine (Circassia)– Company Overview & Analysis
4.13.1 Circassia Marketed Respiratory Inhalers
4.13.1.1 Latest Developments related to Key Marketed Products
4.13.1.1.1 NIOX: Recent Developments
4.13.1.1.2 Tudorza Pressair: Recent Developments
4.13.2 Circassia Respiratory Inhalers R&D Pipeline & Future Outlook
4.13.2.1 Latest Developments related to Key Pipeline Products
4.13.2.1.1 Duaklir Pressair US: Pipeline Developments
4.13.3 Circassia Respiratory Market Forecast, 2017-2028
4.14 H&T Presspart – Company Overview & Analysis
4.14.1 H&T Presspart Marketed Respiratory Inhalers
4.14.1.1 Latest Developments related to the Company
4.14.1.1.1 Recent Developments
4.14.2 H&T Presspart Respiratory Inhalers R&D Pipeline & Future Outlook
4.14.3 H&T Presspart Respiratory Market Forecast, 2017-2028
4.15 Beximco Pharmaceuticals Ltd.– Company Overview & Analysis
4.15.1 Beximco Pharmaceuticals Marketed Respiratory Inhalers
4.15.2 Beximco Respiratory Inhalers R&D Pipeline & Future Outlook
4.15.3 Beximco Respiratory Market Forecast, 2017-2028
4.16 Chiesi Farmaceutici S.p.A. – Company Overview & Analysis
4.16.1 Chiesi Farmaceutici S.p.A Marketed Respiratory Inhalers
4.16.1.1 Latest Developments related to Key Marketed Products
4.16.1.1.1 Trimbow: Recent Developments
4.16.2 Chiesi Farmaceutici Respiratory Inhalers R&D Pipeline & Future Outlook
4.16.2.1 Latest Developments related to Key Pipeline Products
4.16.2.1.1 Bronchitol: Recent development
4.16.2.1.2 CHF 6297: Recent development
4.16.3 Chiesi Farmaceutici: Respiratory Market Forecast, 2017-2028
4.17 Pulmatrix: Company Overview & Analysis
4.17.1 Pulmatrix Respiratory Inhalers R&D Pipeline & Future Outlook
4.17.1.1 Latest Developments related to Key Pipeline Products
4.17.1.1.1 PUR0200-US: Recent development
4.17.1.1.2 PUR1900: Recent development
4.18 Fluidda– Company Overview & Analysis
4.18.1 Latest Developments related to the Company
4.19 Pneuma Respiratory – Company Overview & Analysis
4.19.1 Latest Developments related to the Company
4.20 Amiko Digital Health– Company Overview & Analysis
4.20.1 Amiko Digital Health Marketed Respiratory Inhaler Product

5 Conclusions
5.1 Respiratory Inhalers: A Maturing Market
5.2 The Global Respiratory Inhalers Manufacturers Market In 2018
5.3 Leading Respiratory Inhalers Companies
5.4 Global Respiratory Inhalers Market Forecast 2017-2028
5.5 The Future of the Respiratory Inhalers Market
5.5.1 Growth in Anti-Inflammatory and Combination Drugs
5.5.2 Personalised Medicine
5.5.3 Unmet Needs in Asthma and COPD
5.6 Strategies for Growth In 2018-2028

Appendices
Associated Visiongain Reports
Visiongain Report Sales Order Form
About Visiongain
Visiongain Report Evaluation Form

List of Tables
TABLE 2.1 ADVANTAGES AND DISADVANTAGES OF THE MAIN TYPES OF ASTHMA INHALERS
TABLE 2.2 E-TECHNOLOGY BASED INHALERS
TABLE 3.1 GLOBAL MARKET FORECASTS: REVENUES ($BN), AGR (%) AND CAGR (%), BY LEADING COMPANIES, 2017-2028
TABLE 3.2 LEADING COMPANIES IN RESPIRATORY INHALERS
TABLE 3.3 LEADING RESPIRATORY INHALERS MANUFACTURERS: REVENUES ($BN) AND MARKET SHARES (%), 2018 AND 2028
TABLE 4.1 ASTRAZENECA: COMPANY OVERVIEW, 2018
TABLE 4.2 ASTRAZENECA: PRODUCTS PORTFOLIO, 2018
TABLE 4.3 ASTRAZENECA: PRODUCTS PIPELINE PORTFOLIO, 2018
TABLE 4.4 ASTRAZENECA: RESPIRATORY INHALERS PRODUCTS FORECAST: REVENUE ($BN), AGR (%), CAGR (%), 2017-2028
TABLE 4.5 GLAXOSMITHKLINE: COMPANY OVERVIEW, 2018
TABLE 4.6 GLAXOSMITHKLINE: PRODUCTS PORTFOLIO, 2018
TABLE 4.7 GLAXOSMITHKLINE: PRODUCTS PIPELINE PORTFOLIO, 2018
TABLE 4.8 GLAXOSMITHKLINE: RESPIRATORY INHALERS PRODUCTS FORECAST: REVENUE ($BN), AGR (%), CAGR (%), 2017-2028
TABLE 4.9 BOEHRINGER INGELHEIM: COMPANY OVERVIEW, 2018
TABLE 4.10 BOEHRINGER INGELHEIM: PRODUCTS PORTFOLIO, 2018
TABLE 4.11 BOEHRINGER INGELHEIM: RESPIRATORY INHALERS PRODUCTS FORECAST: REVENUE ($BN), AGR (%), CAGR (%), 2017-2028
TABLE 4.12 TEVA: COMPANY OVERVIEW, 2018
TABLE 4.13 TEVA: PRODUCTS PORTFOLIO, 2018
TABLE 4.14 TEVA: PRODUCTS PIPELINE PORTFOLIO, 2018
TABLE 4.15 TEVA: RESPIRATORY INHALERS PRODUCTS FORECAST: REVENUE ($BN), AGR (%), CAGR (%), 2017-2028
TABLE 4.16 MERCK: COMPANY OVERVIEW, 2018
TABLE 4.17 MERCK: PRODUCTS PORTFOLIO, 2018
TABLE 4.18 MERCK: RESPIRATORY INHALERS PRODUCTS FORECAST: REVENUE ($BN), AGR (%), CAGR (%), 2017-2028
TABLE 4.19 ROCHE: COMPANY OVERVIEW, 2018
TABLE 4.20 ROCHE: PRODUCTS PORTFOLIO, 2018
TABLE 4.21 ROCHE: PRODUCTS PIPELINE PORTFOLIO, 2018
TABLE 4.22 ROCHE: RESPIRATORY INHALERS PRODUCTS FORECAST: REVENUE ($BN), AGR (%), CAGR (%), 2017-2028
TABLE 4.23 NOVARTIS: COMPANY OVERVIEW, 2018
TABLE 4.24 NOVARTIS: PRODUCTS PORTFOLIO, 2018
TABLE 4.25 NOVARTIS: PRODUCTS PIPELINE PORTFOLIO, 2018
TABLE 4.26 NOVARTIS: RESPIRATORY INHALERS PRODUCTS FORECAST: REVENUE ($BN), AGR (%), CAGR (%), 2017-2028
TABLE 4.27 MUNDIPHARMA: COMPANY OVERVIEW, 2018
TABLE 4.28 MUNDIPHARMA: PRODUCTS PORTFOLIO, 2018
TABLE 4.29 MUNDIPHARMA: PRODUCTS PIPELINE PORTFOLIO, 2018
TABLE 4.30 PARI MEDICAL HOLDING: COMPANY OVERVIEW, 2018
TABLE 4.31 PARI MEDICAL HOLDING: PRODUCTS PORTFOLIO, 2018
TABLE 4.32 PARI MEDICAL HOLDING: PRODUCTS PIPELINE PORTFOLIO, 2018
TABLE 4.33 OMRON HEALTHCARE EUROPE B.V: COMPANY OVERVIEW, 2018
TABLE 4.34 OMRON HEALTHCARE EUROPE B.V: PRODUCTS PORTFOLIO, 2018
TABLE 4.35 CIPLA: COMPANY OVERVIEW, 2018
TABLE 4.36 CIPLA: PRODUCTS PORTFOLIO, 2018
TABLE 4.37 SUNOVION PHARMACEUTICALS: COMPANY OVERVIEW, 2018
TABLE 4.38 SUNOVION PHARMACEUTICALS: PRODUCTS PORTFOLIO, 2018
TABLE 4.39 SUNOVION: RESPIRATORY INHALERS PRODUCTS FORECAST: REVENUE ($BN), AGR (%), CAGR (%), 2017-2028
TABLE 4.40 CIRCASSIA: COMPANY OVERVIEW, 2018
TABLE 4.41 CIRCASSIA: PRODUCTS PORTFOLIO, 2018
TABLE 4.42 CIRCASSIA: PRODUCTS PIPELINE PORTFOLIO, 2018
TABLE 4.43 H&T PRESSPART: COMPANY OVERVIEW, 2018
TABLE 4.44 H&T PRESSPART: PRODUCTS PORTFOLIO, 2018
TABLE 4.45 BEXIMCO PHARMACEUTICALS: COMPANY OVERVIEW, 2018
TABLE 4.46 BEXIMCO PHARMACEUTICALS: PRODUCTS PORTFOLIO, 2018
TABLE 4.47 CHIESI FARMACEUTICI S.P.A: COMPANY OVERVIEW, 2018
TABLE 4.48 CHIESI FARMACEUTICI S.P.A: PRODUCTS PORTFOLIO, 2018
TABLE 4.49 CHIESI FARMACEUTICI S.P.A: PRODUCTS PIPELINE PORTFOLIO, 2018
TABLE 4.50 CHIESI FARMACEUTICI S.P.A: RESPIRATORY INHALERS PRODUCTS FORECAST: REVENUE ($BN), AGR (%), CAGR (%), 2017-2028
TABLE 4.51 PULMATRIX: COMPANY OVERVIEW, 2018
TABLE 4.52 PULMATRIX: PRODUCTS PIPELINE PORTFOLIO, 2018
TABLE 4.53 FLUIDDA: COMPANY OVERVIEW, 2018
TABLE 4.54 PNEUMA RESPIRATORY: COMPANY OVERVIEW, 2018
TABLE 4.55 AMIKO DIGITAL HEALTH: COMPANY OVERVIEW, 2018

List of Figures
FIGURE 1.1 GLOBAL RESPIRATORY INHALERS MANUFACTURERS MARKET SEGMENTATION OVERVIEW, 2018
FIGURE 2.1 STEPWISE APPROACH TO TREATMENT OF COPD
FIGURE 3.1 GLOBAL: RESPIRATORY INHALERS PRODUCTS FORECAST: REVENUE ($BN), 2017-2028
FIGURE 3.2 LEADING RESPIRATORY MANUFACTURERS: REVENUE ($BN), 2018
FIGURE 3.3 LEADING RESPIRATORY MANUFACTURERS: MARKET SHARE (%), 2018
FIGURE 3.4 LEADING RESPIRATORY INHALERS MANUFACTURERS: REVENUES ($M), 2028
FIGURE 3.5 LEADING RESPIRATORY INHALERS MANUFACTURERS: MARKET SHARES (%), 2028
FIGURE 4.1 ASTRAZENECA: RESPIRATORY INHALERS PRODUCTS FORECAST: REVENUE ($BN), 2017-2028
FIGURE 4.2 GLAXOSMITHKLINE: RESPIRATORY INHALERS PRODUCTS FORECAST: REVENUE ($BN), 2017-2028
FIGURE 4.3 BOEHRINGER INGELHEIM: RESPIRATORY INHALERS PRODUCTS FORECAST: REVENUE ($BN), 2017-2028
FIGURE 4.4 TEVA: RESPIRATORY INHALERS PRODUCTS FORECAST: REVENUE ($BN), 2017-2028
FIGURE 4.5 MERCK: RESPIRATORY INHALERS PRODUCTS FORECAST: REVENUE ($BN), 2017-2028
FIGURE 4.6 ROCHE: RESPIRATORY INHALERS PRODUCTS FORECAST: REVENUE ($BN), 2017-2028
FIGURE 4.7 NOVARTIS: RESPIRATORY INHALERS PRODUCTS FORECAST: REVENUE ($BN), 2017-2028
FIGURE 4.8 SUNOVION RESPIRATORY INHALERS PRODUCTS FORECAST: REVENUE ($BN), 2017-2028
FIGURE 4.9 CHIESI FARMACEUTICI RESPIRATORY INHALERS PRODUCTS FORECAST: REVENUE ($BN), 2017-2028
FIGURE 5.1 WORLD RESPIRATORY INHALERS MARKET FORECAST: REVENUES ($M), 2017-2028

★調査レポート[呼吸器吸入器製造の世界トップ20社2019] ( Top 20 Global Respiratory Inhalers Manufacturers 2019 / VGN906170) 販売に関する免責事項
[呼吸器吸入器製造の世界トップ20社2019] ( Top 20 Global Respiratory Inhalers Manufacturers 2019 / VGN906170) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆